Equities

Seres Therapeutics Inc

Seres Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.7083
  • Today's Change-0.002 / -0.30%
  • Shares traded2.10m
  • 1 Year change-88.43%
  • Beta1.9698
Data delayed at least 15 minutes, as of Jun 14 2024 21:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Seres Therapeutics, Inc. is a commercial-stage microbiome therapeutics company. It is focused on the development and commercialization of a novel class of biological drugs, which are designed to treat disease by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. Its lead program, VOWST, is to prevent recurrence of Clostridioides difficile infection (CDI) in patients 18 or older following antibacterial treatment for recurrent CDI. Building upon VOWST, it is developing novel microbiome therapeutics, such as SER-155, to specifically target infections and antimicrobial resistance. SER-155, an oral microbiome therapeutic candidate consisting of a consortium of cultivated bacteria, is designed to prevent enteric-derived infections and resulting blood stream infections and induce immune tolerance responses to reduce the incidence of GvHD in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).

  • Revenue in USD (TTM)126.85m
  • Net income in USD-82.68m
  • Incorporated2010
  • Employees233.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
PDS Biotechnology Corp0.00-43.89m102.15m25.00--2.75-----1.37-1.370.001.010.00----0.00-63.85-51.63-74.22-59.00-----------27.820.3933-------5.11------
Allakos Inc0.00-214.44m102.71m131.00--0.9789-----2.45-2.450.001.180.00----0.00-81.27-42.71-92.78-45.11------------0.00------41.96---38.89--
Beyondspring Inc1.75m-21.03m103.04m35.00------58.84-0.5392-0.53920.0449-0.68680.0493----48,638.89-61.80-75.50-88.85-96.48-----1,253.46-4,977.12--------29.61--36.82---13.54--
Sangamo Therapeutics Inc18.76m-328.05m103.78m405.00--1.80--5.53-1.86-1.860.10570.27840.0659--4.8646,311.11-115.20-26.09-139.17-31.04-----1,749.06-136.53----0.00--58.3415.85-34.09---13.25--
Hongchang International Co Ltd2.67m-365.80k103.82m8.00--2.62--38.93-0.0006-0.00060.00550.07630.0993--175.86---1.36-7.98-1.42-10.943.0311.47-13.72-64.885.86--0.2263--3,289.22---42.63------
Coya Therapeutics Inc6.13m-10.30m105.25m8.00--3.25--17.17-0.8899-0.88990.54012.220.2236----766,131.30-37.59---41.86-------168.11------0.00------34.77------
Immunic Inc0.00-97.92m107.19m77.00--1.28-----1.84-1.840.000.92780.00----0.00-91.94-72.09-110.91-80.11------------0.00------22.25---10.97--
Seres Therapeutics Inc126.85m-82.68m107.27m233.00------0.8457-0.6062-0.60620.9495-0.39450.4149----544,407.80-27.04-41.51-36.82-54.13-----65.18-170.141.25-9.212.41--1,672.2434.9154.54--32.72--
CytomX Therapeutics Inc119.18m16.53m107.53m120.006.98--5.790.90230.19780.19781.53-0.46490.5684--16.71993,150.007.89-21.5326.77-32.32----13.87-100.38--------90.3811.2199.43---26.01--
Adicet Bio Inc0.00-139.79m110.93m143.00--0.4286-----2.95-2.950.003.150.00----0.00-46.75-37.03-49.70-40.28-------748.46----0.00---100.00---104.41--65.27--
FibroGen Inc167.49m-240.46m111.41m486.00------0.6652-2.45-2.451.70-2.290.37041.185.05344,635.80-53.71-30.62-124.24-42.3175.4693.52-145.02-119.081.27-36.51----4.99-7.053.21---20.67--
Amylyx Pharmaceuticals Inc398.00m-71.10m111.53m384.00--0.3436--0.2802-1.07-1.075.744.770.96446.7421.001,036,461.00-17.23---20.84--88.93---17.86--4.48--0.00--1,612.94--124.84------
Omega Therapeutics Inc4.94m-92.28m111.96m93.00--2.71--22.67-1.67-1.670.08960.74980.029--6.0853,107.53-54.28---62.10-------1,868.35------0.302--49.25--5.13------
Karyopharm Therapeutics Inc140.46m-146.34m112.59m325.00------0.8016-1.28-1.281.22-1.450.52981.674.24432,187.70-55.19-53.02-72.56-65.8596.0897.18-104.18-125.152.99-9.662.25---7.0336.9313.43------
Citius Pharmaceuticals Inc0.00-37.35m113.03m22.00--1.25-----0.2367-0.23670.000.49890.00----0.00-37.14-30.26-39.48-32.11------------0.00-------0.1589------
Data as of Jun 14 2024. Currency figures normalised to Seres Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

33.88%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 31 Mar 202422.65m15.00%
The Vanguard Group, Inc.as of 31 Mar 20246.58m4.36%
BlackRock Fund Advisorsas of 31 Mar 20246.26m4.15%
Hudson Bay Capital Management LPas of 31 Mar 20245.43m3.59%
Geode Capital Management LLCas of 31 Mar 20242.13m1.41%
Woodline Partners LPas of 31 Mar 20242.05m1.36%
SSgA Funds Management, Inc.as of 31 Mar 20241.95m1.29%
BofA Securities, Inc.as of 31 Mar 20241.63m1.08%
Eversept Partners LPas of 31 Mar 20241.39m0.92%
Handelsbanken Fonder ABas of 31 Mar 20241.10m0.73%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.